Catalog No.
Product Name
Application
Product Information
Citations
-
KRas Inhibitor
Spiclomazine hydrochloride is a KRas inhibitor recognized for its dual role as an antipsychotic and antitumor agent. This compound effectively induces apoptosis in cancer cells, making it a valuable tool in cancer research. Its action on KRas allows for exploration into the mechanisms of tumorigenesis and potential therapeutic strategies targeting KRas-driven malignancies. -
RAS Activator
RAS Activator Compound 1 is a specific activator targeting the guanine nucleotide exchange factor, son of sevenless homologue 1 (SOS1). This compound effectively facilitates the nucleotide exchange process, leading to increased levels of active RAS-GTP in HeLa cells. RAS Activator Compound 1 is valuable for research focused on RAS-driven tumors, providing insights into the mechanisms of RAS activation and its role in cancer biology. -
Anti-cancer Agent
KRAS G12C inhibitor 39 is a selective inhibitor targeting the KRAS G12C mutation, which is frequently associated with various cancers. This compound demonstrates significant anti-tumor activity by interfering with KRAS signaling pathways, making it a valuable tool for research into KRAS G12C-mediated oncogenesis. Its application extends to studies aimed at understanding the efficacy of targeted therapies in KRAS-driven malignancies. -
KRAS Inhibitor
AMG410 diTFA is a selective pan-KRAS inhibitor targeting various KRAS mutations, including G12D, G12V, and G13D, with IC50 values ranging from 1 to 4 nM. It exhibits over 100-fold selectivity against HRAS and NRAS and acts as a dual inhibitor of GTP-bound and GDP-bound states (Kd(GDP) of 1 nM; Kd(GTP) of 22 nM). AMG410 diTFA effectively disrupts KRAS signaling irrespective of cycling state and inhibits proliferation in wild-type KRAS-amplified tumor cells. This compound is valuable for research on colorectal, pancreatic, and lung cancers. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 47 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 0.172 µM. It effectively inhibits p-ERK signaling, with IC50 values of 0.046 µM in MIA PaCA-2 cells and 69.8 µM in A549 cells. This compound is a valuable tool for researching therapeutic strategies in pancreatic, colorectal, and lung cancers. -
KRAS G12C Inhibitor
KRAS Inhibitor-15 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting a potent IC50 of 0.954 µM. This compound demonstrates effective inhibition of phosphorylated ERK (p-ERK) with IC50 values of 2.03 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. KRAS Inhibitor-15 is suitable for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers, contributing to the understanding of KRAS-driven tumorigenesis. -
KRAS G12D Inhibitor
KRAS G12D-IN-32 is a selective inhibitor of the KRAS G12D mutant protein, which plays a critical role in various oncogenic pathways. This compound is instrumental for investigating the molecular mechanisms underlying adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Researchers can employ KRAS G12D-IN-32 to explore therapeutic strategies targeting KRAS mutations and to evaluate potential treatment responses in cancer models. -
Epac Activator
8-pCPT-2′-O-Me-cAMP is a selective activator of exchange proteins activated by cAMP (Epac), specifically targeting Epac1 with an EC50 of 2.2 μM. This compound does not activate protein kinase A (PKA) with an EC50 greater than 10 μM. 8-pCPT-2′-O-Me-cAMP effectively stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro, and it plays a role as a Rap1 activator. Additionally, it enhances the barrier function of retinal pigment epithelium against choroidal endothelial cell invasion, potentially providing insights into therapeutic mechanisms for macular degeneration. -
KRASG12C Inhibitor
KRASG12C IN-17 is an orally active covalent inhibitor targeting the KRASG12C mutation. It demonstrates potent inhibitory effects on KRASG12C-mutant cancer cell lines, with IC50 values of 0.7 nM in NCI-H23 and 0.5 nM in NCI-H358. This compound irreversibly binds to KRASG12C, achieving over 96% modification efficiency in both GDP-bound and GMPPNP-bound states. KRASG12C IN-17 is valuable for research focused on KRAS-driven malignancies, particularly in the context of colorectal cancer. -
Anti-cancer Agent
KRAS G12C inhibitor 35 is a selective inhibitor targeting the KRAS G12C mutation, a driver mutation frequently associated with various cancers. This compound effectively disrupts KRAS signaling pathways, leading to inhibition of tumor cell proliferation. It serves as a valuable tool for research into KRAS G12C-mediated oncogenesis and therapeutic strategies in cancer treatment. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 30 is a selective inhibitor targeting the KRAS G12C mutation. This compound demonstrates significant anti-tumor activity by disrupting the downstream signaling pathways associated with oncogenic KRAS. It is primarily utilized in cancer research, particularly in studies focused on therapies for KRAS-driven malignancies. -
KRAS Dimerizing Agent
PPI stabilizer-1 is a KRAS dimerizing agent that effectively promotes the dimerization of KRAS with a dissociation constant (KD) of 3.8 µM. This compound has the ability to co-crystallize with GCP-KRASG12D, facilitating structural studies and elucidating the role of KRAS in cellular signaling. PPI stabilizer-1 is valuable for researching KRAS-driven cancers, providing insights into therapeutic strategies targeting this critical pathway. -
KRAS Ligand
KRAS Ligand 3 is a target-binding ligand for KRAS that interacts with the KRAS inhibitor, enhancing its efficacy. This compound demonstrates synergistic effects in tumor growth inhibition, making it a valuable tool for research in cancer biology and therapeutic development. Its application in studying KRAS-related signaling pathways can provide insights into tumorigenesis and potential treatment strategies. -
K-Ras Antagonist
K-Ras-IN-2 is a selective antagonist of the K-Ras protein. It has demonstrated significant biological activity in inhibiting K-Ras-driven signaling pathways, making it a valuable tool for researchers studying tumor biology and oncogenic signaling. This compound is particularly useful in cancer research applications focused on K-Ras-related malignancies. -
KRAS Inhibitor
COTI-219 is an orally active inhibitor of the KRAS protein, targeting its role in oncogenic signaling pathways. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. COTI-219 is utilized in studies aimed at understanding KRAS-related signaling mechanisms and evaluating therapeutic strategies for KRAS-driven tumors. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 48 is a potent inhibitor targeting the KRAS G12C mutation, with an IC50 of 639.91 nM. This compound demonstrates significant anti-proliferative activity in various cancer cell lines, exhibiting IC50 values of 0.796 µM in H358, 6.33 µM in H23, and 16.14 µM in A549 cells. It serves as a valuable tool for research into KRAS-driven malignancies and therapeutic strategies targeting mutant KRAS. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 59 selectively targets the KRAS G12C mutant protein, inhibiting its downstream signaling pathways. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on KRAS-driven malignancies. It holds potential for further exploration in therapeutic applications against cancers harboring the KRAS G12C mutation. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 23 is a selective inhibitor targeting the KRAS G12C mutation. It effectively inhibits H358 cells with an IC50 value of 491 nM, demonstrating its potential in cancer research. This compound is primarily utilized in studies focused on KRAS-driven cancers for therapeutic development and efficacy evaluation. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 25 primarily targets the KRAS G12C mutant by inhibiting the SOS1-assisted GDP/GTP exchange activity, demonstrating an IC50 of 0.48 nM. This compound has potential applications in therapeutic research aimed at KRAS-driven cancers, providing a valuable tool for studying the role of KRAS mutations in tumorigenesis and evaluating potential treatment strategies. -
KRAS G12D Inhibitor
KRAS G12D Inhibitor 15 is a selective inhibitor targeting the KRAS G12D mutation, a critical player in various cancer pathways. This compound demonstrates significant potential in studies related to cancer progression and metastasis. Additionally, KRAS G12D Inhibitor 15 features an alkyne moiety, enabling its use in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, making it a valuable tool for chemical biology applications. -
Ra Inhibitor
pan-KRAS-IN-17 is a potent inhibitor targeting pan-KRAS. This compound effectively disrupts KRAS signaling pathways, demonstrating significant activity in various cancer models characterized by KRAS mutations. It is a valuable tool for research into KRAS-driven malignancies and for investigating therapeutic approaches aimed at inhibiting malignant cell proliferation and survival. -
Anti-cancer Agent
KRAS G12D inhibitor 11 is a potent inhibitor targeting the KRAS G12D mutation, a critical driver of various cancers. This compound interferes with the signaling pathways mediated by the Ras family of proteins, which are essential for cellular proliferation and survival. KRAS G12D inhibitor 11 is applicable in research focused on KRAS G12D-mediated oncogenesis and therapeutic development for related malignancies. -
Ras Inhibitor
StRIP16 is a bioavailable analogue of StRIP3 that functions as a Ras inhibitor. This double-stapled peptide exhibits high specificity for Rab8a GTPase, with a dissociation constant (Kd) of 12.7 μM. StRIP16 is utilized in research to investigate the role of Rab8a in cellular signaling pathways and its implications in various cancer models. -
Ra Inhibitor
ISIS 2503 is a 20-mer antisense oligonucleotide specifically designed to inhibit the expression of Ha-Ras. By targeting the mRNA of Ha-Ras, ISIS 2503 effectively reduces its protein levels, thereby modulating downstream signaling pathways associated with cell proliferation and survival. This reagent is valuable for research applications focused on cancer biology and the study of oncogenic signaling mechanisms. -
pan-KRAS Inhibitor
pan-KRAS-IN-3 is a pan-KRAS inhibitor designed to target and inhibit KRAS signaling pathways, which are commonly implicated in various cancers. This compound serves as a useful tool for cancer research by effectively blocking KRAS activity, thereby offering insights into tumor biology and potential therapeutic strategies. Additionally, pan-KRAS-IN-3 features an alkyne group enabling its participation in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating the development of novel chemical probes and conjugates in experimental studies. -
KRAS G12D inhibitor
KRAS G12D inhibitor 19 is a selective inhibitor targeting the KRAS G12D mutant protein, which plays a pivotal role in driving oncogenic signaling pathways in various cancers. This compound exhibits significant anti-proliferative activity against KRAS G12D-driven tumor cell lines. It serves as a valuable tool in cancer research, particularly for studying the efficacy of KRAS-targeted therapies and understanding the mechanistic pathways involved in KRAS-related malignancies. -
Rho GTPase Inhibitor
Rho GTPase Inhibitor 1 is a selective inhibitor targeting Rho GTPases, with demonstrated high affinity for Cdc42, Rac1, and RhoA, exhibiting KDs of 151, 352, and 232 μM, respectively. This compound effectively reduces cell migration in glioma cell lines, highlighting its potential utility in cancer research and therapeutic development. Its role in modulating Rho GTPase signaling makes it a valuable tool for investigating cellular processes such as motility and invasion. -
KRAS Mutant Inhibitor
KRAS-IN-48 is a selective inhibitor targeting KRAS mutations, exhibiting Kd values of 2.58 nM for the KRAS-G12D variant and 5.49 μM for KRAS-G12V. This compound demonstrates significant biological activity against KRAS mutant proteins, making it an important tool in cancer research. KRAS-IN-48 is particularly valuable for studies focused on understanding the role of KRAS mutations in tumorigenesis and therapeutic response. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 57 is a selective and covalent inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 0.21 μM in KRAS G12C/SOS1 binding assays. This compound effectively induces apoptosis in cancer cells, making it a valuable tool for studying KRAS-driven malignancies. Its oral bioavailability enhances its suitability for in vivo research applications focused on cancer therapeutics targeting KRAS mutations. -
KRAS G12D Inhibitor
KRAS G12D inhibitor 6 is a selective inhibitor targeting the KRAS G12D mutant, a significant oncogenic driver in various cancers. This compound demonstrates strong inhibitory activity that can facilitate the study of KRAS-mediated signaling pathways and tumor progression. It serves as a valuable tool in cancer research, particularly in developing targeted therapies against KRAS-driven malignancies. -
KRAS Inhibitor
KRAS Inhibitor-37 targets the KRAS protein, exhibiting high affinity with KDs of 0.004 nM, 0.041 nM, 0.019 nM, and 0.144 nM for KRAS wild type, G12D, G12C, and G12V variants, respectively, as determined by SPR binding assays. This compound demonstrates significant anti-proliferative activity, with IC50 values ranging from <2 nM to 14 nM across various cancer cell lines, including H358, SW620, and PANC08.13. KRAS Inhibitor-37 is a valuable tool for advancing research in cancer biology, particularly in studies focused on KRAS-driven malignancies. -
KRAS Inhibitor
KRAS Inhibitor-35 (compound 72) is a potent inhibitor of KRAS with an IC50 of 2 nM. It effectively disrupts KRAS signaling pathways, making it a valuable tool for studying tumor biology and the role of KRAS mutations in cancer research. This compound is suitable for various in vitro and in vivo applications aimed at exploring therapeutic strategies targeting KRAS-driven malignancies. -
Anti-cancer Agent
KRAS G12C inhibitor 38 is a selective inhibitor targeting the mutant form of KRAS G12C, an essential component of intracellular signaling pathways involved in cellular growth and proliferation. This compound exhibits significant anti-cancer activity and is primarily applied in research focused on KRAS G12C-driven malignancies. Its utilization can aid in the exploration and understanding of therapeutic strategies against cancers characterized by KRAS mutations. -
Target Protein Ligand-Linker Conjugate
KRAS G12C Ligand-Linker Conjugates 1 is a conjugate formed from the KRAS G12C ligand and a linker moiety. This compound is designed to facilitate the targeted degradation of KRAS G12C proteins through the synthesis of PROTAC YF135. It serves as a valuable tool for studying KRAS-related signaling pathways and exploring therapeutic strategies in KRAS-driven cancers. -
KRAS G12C Inhibitor
KRAS inhibitor-18 is a selective inhibitor targeting the KRAS G12C mutation, demonstrating a potent inhibitory effect with an IC50 of 4.74 µM. This compound effectively inhibits phosphorylated ERK in MIA PaCA-2 and A549 cell lines, with IC50 values of 66.4 µM and 11.1 µM, respectively. KRAS inhibitor-18 is valuable for research applications in pancreatic, colorectal, and lung cancer studies, facilitating investigations into KRAS-driven tumorigenesis and potential therapeutic interventions. -
SOS2 Ligand
SOS2 Ligand 1 is a selective ligand that targets son of sevenless 2 (SOS2), exhibiting a KD value of 4.6 µM. This compound is valuable for studying the role of SOS2 in cellular signaling pathways and may facilitate research in cancer biology and related fields. Its specificity for SOS2 makes it a useful tool for investigating SOS2-mediated processes and potential therapeutic interventions. -
Farnesyl Thiosalicylic Acid Derivative
Farnesyl thiosalicylic acid amide (FTS-A) is an orally active derivative that targets the farnesyl thiosalicylic acid pathway. It effectively reduces Ras-GTP levels, demonstrating significant inhibition of cell growth in Panc-1 and U87 cell lines, with IC50 values of 20 μM and 10 μM, respectively. This compound is relevant for cancer research, offering potential insights into Ras signaling and therapeutic strategies. -
GTPase Inhibitor
RTIL 13 is a selective inhibitor of dynamin GTPase, demonstrating an IC50 value of 2.3 μM for dynamin I. Additionally, it interacts with the pleckstrin homology lipid-binding domain. RTIL 13 effectively inhibits receptor-mediated endocytosis and synaptic vesicle endocytosis, with IC50 values of 9.3 μM and 7.1 μM, respectively. This compound is valuable for research focused on vesicle trafficking and cellular uptake mechanisms. -
Ras Signaling Modulator
Palmostatin M is a Ras signaling modulator that specifically targets acyl-protein thioesterases 1 and 2 (APT1 and APT2), exhibiting an IC50 of 2.5 nM for APT1. By disrupting the depalmitoylation cycle of Ras, Palmostatin M effectively downregulates the Ras signaling pathway. This compound is particularly relevant for studies investigating cancer biology and the modulation of Ras-driven signaling networks. -
KRASG12D Mutants Inhibitor
KRAS-IN-42 is a covalent inhibitor specifically targeting KRASG12D mutants. This compound exhibits potent activity against KRASG12D-driven cancers, including non-small cell lung cancer and colorectal cancer. It is a valuable tool for researchers studying the molecular mechanisms and therapeutic options for KRASG12D-mutant oncogenesis. -
KRAS G12D Modulator
KRAS G12D modulator-1 is an effective modulator targeting the KRAS G12D mutation. It exhibits potent activity with IC50 values ranging from 1 to 10 μM against NEA-G12D, PPI-G12D, and phosphorylated ERK in AGS cells. This compound is suitable for research applications focused on cancer biology and the modulation of KRAS signaling pathways. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 43 is a selective inhibitor targeting the KRAS G12C mutation, a key driver in various cancers. It demonstrates significant anti-migration and anti-proliferative activities, with IC50 values ranging from 0.001 to 1 µM in H358, A549, and HCC cell lines. This compound holds potential for research applications focused on cancer progression and therapeutic development against KRAS-driven malignancies. -
KRAS Inhibitor
KRAS-IN-41 is a potent inhibitor of the KRAS oncogene, exhibiting IC50 values of less than 0.01 μM against both KRAS G12D and KRAS G12V variants. This compound effectively inhibits the proliferation of RAS mutant cell lines, including GP2D and SW620, demonstrating its potential for therapeutic application. KRAS-IN-41 is suitable for use in cancer research, particularly in studies focused on targeting KRAS mutations. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 50 is a potent small molecule that selectively targets the KRAS G12C mutant protein, exhibiting an IC50 of 46.7 nM. This compound is instrumental in cancer research, particularly in studies focused on KRAS-driven tumors. Its ability to inhibit KRAS G12C activity makes it a valuable tool for investigating therapeutic strategies and potential treatments for malignancies associated with this mutation. -
KRAS Inhibitor
KRAS-IN-47 is a potent inhibitor of the KRAS protein, specifically targeting the KRAS G12V mutant with an IC50 of less than 50 nM. This compound is valuable for research applications focused on understanding KRAS-driven cancers, providing insights into tumor biology and therapeutic resistance mechanisms. The inhibitor's efficacy in modulating KRAS activity makes it a critical tool for studying the role of this oncogene in cancer progression and treatment response. -
KRAS G12D Inhibitor
KRAS G12D inhibitor 28 selectively targets the KRAS G12D mutation, a common oncogenic driver in various cancers. This compound exhibits potent inhibitory activity, making it a valuable tool for studying KRAS-driven tumor biology and developing targeted therapies. Its application in cancer research aids in understanding the molecular mechanisms of KRAS mutations and their role in tumor progression. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 55 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound effectively disrupts KRAS signaling pathways, leading to inhibited cell proliferation in cancer models. It is primarily utilized in research focused on the development of targeted therapies for tumors harboring KRAS G12C mutations. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 51 is a selective inhibitor targeting the mutant form of the KRAS protein, specifically the G12C variant. This compound exhibits significant biological activity in suppressing KRAS-driven signaling pathways, making it a valuable tool for cancer research, particularly in studies focused on tumors harboring KRAS G12C mutations. Its application extends to investigating therapeutic strategies and screening for potential drug candidates in KRAS-related malignancies. -
Ras Modulator
Ras Modulator-1 is a selective modulator of the Ras protein, which plays a critical role in cell signaling pathways associated with growth and differentiation. This compound has been shown to influence the activity of Ras, making it a valuable tool for investigating cancer biology and therapeutic interventions targeting Ras-driven malignancies. Research applications include studying signal transduction mechanisms and evaluating potential treatments in oncogenic signaling pathways. -
KRASG12C Inhibitor
SML-8-73-1 is a nucleotide-based inhibitor targeting KRASG12C. This compound demonstrates significant efficacy in inhibiting the activity of KRASG12C, making it a valuable tool for research into non-small cell lung cancer (NSCLC). Its selective inhibition allows for the exploration of KRAS-related signaling pathways and contributes to the understanding of cancer progression and potential therapeutic interventions.
